{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:35:21Z","timestamp":1787495721211,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32 CA009566"],"award-info":[{"award-number":["T32 CA009566"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32 GM007019"],"award-info":[{"award-number":["T32 GM007019"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clgc.2016.08.011","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T14:33:22Z","timestamp":1473777202000},"page":"207-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma"],"prefix":"10.1016","volume":"15","author":[{"given":"Randy F.","family":"Sweis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Medved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Towey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Karczmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aytekin","family":"Oto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell Z.","family":"Szmulewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Fishkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Karrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.08.011_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clgc.2016.08.011_bib2","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.clgc.2016.08.011_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.011_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.diii.2013.01.019","article-title":"Radiological evaluation of response to treatment: application to metastatic renal cancers receiving anti-angiogenic treatment","volume":"95","author":"Ammari","year":"2014","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.clgc.2016.08.011_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jmri.10176","article-title":"Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions","volume":"16","author":"Padhani","year":"2002","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.clgc.2016.08.011_bib6","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1200\/JCO.2005.04.143","article-title":"Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study","volume":"23","author":"Liu","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.011_bib7","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1200\/JCO.2003.08.092","volume":"21","author":"Morgan","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.011_bib8","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1158\/1078-0432.CCR-07-0238","article-title":"Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging","volume":"13","author":"Jackson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.08.011_bib9","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/JCO.2007.15.5655","article-title":"Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma","volume":"26","author":"Hahn","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.011_bib10","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1158\/1535-7163.MCT-10-0477","article-title":"Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling","volume":"9","author":"Bhatt","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2016.08.011_bib11","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-09-3965","article-title":"Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2016.08.011_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jmri.20061","article-title":"Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: variability and changes in tumor tissue over time","volume":"20","author":"Medved","year":"2004","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.clgc.2016.08.011_bib13","first-page":"343","article-title":"In vivo T1 and T2 measurements of muskuloskeletal tissue at 3T and 1.5T","volume":"183","author":"Han","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.clgc.2016.08.011_bib14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mrm.10737","article-title":"New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors","volume":"51","author":"Fan","year":"2004","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.clgc.2016.08.011_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10334-005-0022-y","article-title":"Multi-slice DCE-MRI data using P760 distinguishes between metastatic and non-metastatic rodent prostate tumors","volume":"19","author":"Fan","year":"2006","journal-title":"MAGMA"},{"key":"10.1016\/j.clgc.2016.08.011_bib16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.mri.2006.10.011","article-title":"Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI","volume":"25","author":"Fan","year":"2007","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.clgc.2016.08.011_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","article-title":"Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols","volume":"10","author":"Tofts","year":"1999","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.clgc.2016.08.011_bib18","doi-asserted-by":"crossref","first-page":"6302S","DOI":"10.1158\/1078-0432.CCR-040031","article-title":"Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan Kettering Cancer Center experience","volume":"10","author":"Motzer","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.08.011_bib19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:26:08Z","timestamp":1761564368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316302452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1558767316302452"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.08.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}